To accomplish this goal, the team works with the world’s largest family with a single genetic mutation leading to Alzheimer’s disease before the age of 40. This is a very rare group, as more than 95% of the individuals with Alzheimer’s disease are older than 65. In addition to investigating biomarkers of Alzheimer’s disease in this unique family, MAPP supports research that aims to advance our understanding of Alzheimer’s disease and related dementias and prevention of cognitive decline in culturally diverse populations. This program will allow studies at the Universidad del Sagrado Corazón in Puerto Rico and the Massachusetts Institute of Technology. And once it does, they will continue to inspire the future leaders in STEM to tackle the diseases of tomorrow.
Source: Forbes March 25, 2020 09:02 UTC